Clene Inc. Advances Promising Therapy for ALS, Targets Accelerated FDA Approval
Clene Inc. reports significant progress on CNM-Au8, a potential breakthrough therapy for amyotrophic lateral sclerosis (ALS), with plans to submit a New Drug Application under the FDA's Accelerated Approval pathway in Q4 2025. New data demonstrates improved patient survival and neurological repair.
Clene Inc. is advancing its investigational therapy CNM-Au8 for amyotrophic lateral sclerosis (ALS), with promising data supporting a potential New Drug Application (NDA) under the FDA's Accelerated Approval pathway in the fourth quarter of 2025. Recent clinical findings reveal significant improvements in survival rates for patients with more severe ALS, marking a potential breakthrough in treating this challenging neurodegenerative disease.
The company's research extends beyond ALS, with Phase 2 extension results in multiple sclerosis (MS) demonstrating potential for remyelination and neuronal repair. CNM-Au8 targets mitochondrial function and the NAD pathway, potentially offering a novel approach to treating neurological disorders by improving central nervous system cell survival and reducing oxidative stress.
Financially, Clene reported a first quarter net loss of $0.8 million, with $9.8 million in cash reserves to fund operations through the third quarter of 2025. The company's strategic focus on developing therapies for neurodegenerative diseases positions it at the forefront of innovative neurological treatment research.
The potential FDA Accelerated Approval could significantly expedite patient access to a promising new treatment for ALS, a disease with limited therapeutic options. If successful, this could represent a critical advancement in managing a progressive and devastating neurological condition that currently lacks comprehensive treatment strategies.